11月26日，恒瑞医药盘中上涨2.14%，截至09:49，报62.18元/股，成交5.87亿元，换手率0.15%，总市值 4127.01亿元。 资金流向方面，主力资金净流入7527.32万元，特大单买入8020.23万元，占比13.65%，卖出2830.32万 元，占比4.82%；大单买入1.41亿元，占比24.08%，卖出1.18亿元，占比20.10%。 恒瑞医药今年以来股价涨36.06%，近5个交易日涨1.75%，近20日跌2.87%，近60日跌4.78%。 资料显示，江苏恒瑞医药股份有限公司位于江苏连云港市经济技术开发区昆仑山路7号,中国香港铜锣湾 希慎道33号利园1期19楼1920室，成立日期1997年4月28日，上市日期2000年10月18日，公司主营业务涉 及江苏恒瑞医药股份有限公司是一家主要从事药品的研发、生产和销售的中国公司。该公司专注于肿瘤 领域，覆盖激酶抑制剂、抗体偶联药物（ADC）、肿瘤免疫、激素受体调控、脱氧核糖核酸（DNA） 修复及表观遗传、支持治疗等研究领域。该公司的产品包括抗肿瘤、镇痛麻醉和造影剂，应用于自身免 疫疾病、代谢性疾病、心血管疾病、感染疾病、呼吸系统疾病、血液疾病、疼 ...

资料显示，深圳翰宇药业股份有限公司位于广东省深圳市龙华区观澜高新园区观盛四路7号翰宇创新产 业大楼，成立日期2003年4月2日，上市日期2011年4月7日，公司主营业务涉及化学制药和医疗器械。主 营业务收入构成为：医药制造业100.00%。 翰宇药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、仿制药、创新 药、华为概念、创投等。 截至9月30日，翰宇药业股东户数11.01万，较上期增加74.86%；人均流通股6771股，较上期减少 42.81%。2025年1月-9月，翰宇药业实现营业收入6.83亿元，同比增长82.06%；归母净利润7135.15万 元，同比增长305.00%。 11月24日，翰宇药业盘中上涨2.09%，截至09:51，报18.11元/股，成交9499.71万元，换手率0.71%，总 市值159.96亿元。 资金流向方面，主力资金净流入518.97万元，特大单买入403.93万元，占比4.25%，卖出0.00元，占比 0.00%；大单买入1398.45万元，占比14.72%，卖出1283.41万元，占比13.51%。 翰宇药业今年以来股价涨40.50%，近5个交易 ...

Core Viewpoint - Zai Lab's stock price has shown significant volatility, with a year-to-date increase of 64.82%, but a recent decline of 3.11% over the past five trading days, indicating potential market fluctuations and investor sentiment shifts [1][2]. Company Overview - Zai Lab, established on March 18, 2009, and listed on January 23, 2020, is based in Kunshan, Jiangsu Province, focusing on the research, production, and sales of chemical and biological new drugs [1]. - The company's main revenue source is pharmaceuticals, accounting for 99.97% of its business, with minimal contributions from intermediates and asset leasing [1]. Financial Performance - For the period from January to September 2025, Zai Lab reported a revenue of 593 million yuan, reflecting a year-on-year growth of 54.49%. However, the net profit attributable to shareholders was a loss of 93.42 million yuan, showing a slight increase in loss of 4.58% compared to the previous period [2]. Shareholder Structure - As of September 30, 2025, Zai Lab had 8,809 shareholders, a slight increase of 0.16% from the previous period. The average number of circulating shares per shareholder decreased by 0.16% to 30,049 shares [2]. - Notable institutional shareholders include China Europe Medical Health Mixed A and ICBC Frontier Medical Stock A, with varying changes in their holdings [2].

资料显示，舒泰神(北京)生物制药股份有限公司位于北京市北京经济技术开发区经海二路36号，成立日 期2002年8月16日，上市日期2011年4月15日，公司主营业务涉及主要从事生物制品和部分化学药品的研 发、生产和销售。主营业务收入构成为：注射用鼠神经生长因子(苏肽生)59.17%，复方聚乙二醇电解质 散33.19%，其他7.63%。 舒泰神所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、抗癌治癌、创 新药、仿制药、AI医药等。 11月19日，舒泰神盘中下跌2.02%，截至09:54，报34.02元/股，成交2.87亿元，换手率1.84%，总市值 162.54亿元。 资金流向方面，主力资金净流出2941.53万元，特大单买入1076.11万元，占比3.75%，卖出2220.02万 元，占比7.74%；大单买入5187.11万元，占比18.10%，卖出6984.73万元，占比24.37%。 舒泰神今年以来股价涨359.11%，近5个交易日跌8.62%，近20日跌11.45%，近60日跌41.65%。 今年以来舒泰神已经8次登上龙虎榜，最近一次登上龙虎榜为10月31日，当日龙虎榜净买入3. ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 182.83%, but a recent decline in the last 20 and 60 days, indicating potential market concerns [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002, with its IPO on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported operating revenue of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new institutional shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several other funds entering the top ten circulating shareholders [3]. Market Activity - On November 19, Yipinhong's stock price fell by 2.01% to 48.25 yuan per share, with a trading volume of approximately 49.77 million yuan and a turnover rate of 0.24%. The total market capitalization is 21.794 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].

今年以来一品红已经5次登上龙虎榜，最近一次登上龙虎榜为7月21日，当日龙虎榜净买入6557.61万 元；买入总计3.05亿元 ，占总成交额比20.96%；卖出总计2.40亿元 ，占总成交额比16.46%。 资料显示，一品红药业集团股份有限公司位于广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大 厦15-19层，成立日期2002年2月4日，上市日期2017年11月16日，公司主营业务涉及自有药品的研发、 生产和销售及代理药品的销售。主营业务收入构成为：儿童药61.12%，慢病药22.71%，其他16.17%。 一品红所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：AI医药、DeepSeek概念、 创新药、疫苗、年度强势等。 11月18日，一品红盘中下跌2.02%，截至10:11，报49.00元/股，成交8701.02万元，换手率0.42%，总市 值221.33亿元。 资金流向方面，主力资金净流出211.05万元，特大单买入561.18万元，占比6.45%，卖出0.00元，占比 0.00%；大单买入794.01万元，占比9.13%，卖出1566.23万元，占比18.00%。 一品红今年以来股价 ...

Group 1 - The core viewpoint of the news is that 恒瑞医药's stock has experienced fluctuations, with a recent decline of 2.00% and a year-to-date increase of 34.88% [1] - As of November 17, the stock price is reported at 61.64 CNY per share, with a total market capitalization of 409.12 billion CNY [1] - The company has seen a net outflow of 1.92 million CNY in principal funds, with significant selling pressure observed [1] Group 2 - 恒瑞医药, established on April 28, 1997, focuses on the research, production, and sales of pharmaceuticals, particularly in the oncology field [2] - The company's main revenue sources are product sales (86.88%), licensing income (12.63%), and other income (0.49%) [2] - The company operates in various therapeutic areas, including oncology, pain management, and cardiovascular diseases [2] Group 3 - As of September 30, the number of shareholders has increased to 397,300, while the average circulating shares per person have decreased by 8.21% [3] - For the period from January to September 2025, 恒瑞医药 reported a revenue of 23.188 billion CNY, reflecting a year-on-year growth of 14.85%, and a net profit of 5.751 billion CNY, up 24.50% year-on-year [3] Group 4 - Since its A-share listing, 恒瑞医药 has distributed a total of 9.303 billion CNY in dividends, with 3.568 billion CNY distributed in the last three years [4] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 487 million shares, a decrease of 48.179 million shares from the previous period [4] - Other notable shareholders include China Securities Finance Corporation and various ETFs, with some experiencing a reduction in shareholding [4]

睿智医药所属申万行业为：医药生物-医疗服务-医疗研发外包。所属概念板块包括：创新药、抗癌治 癌、AI医药、CRO概念、阿尔茨海默等。 11月14日，睿智医药盘中上涨2.40%，截至10:48，报11.52元/股，成交1.04亿元，换手率1.94%，总市值 57.37亿元。 资金流向方面，主力资金净流入182.84万元，特大单买入378.07万元，占比3.62%，卖出343.06万元，占 比3.29%；大单买入2199.10万元，占比21.06%，卖出2051.27万元，占比19.65%。 睿智医药今年以来股价涨79.44%，近5个交易日涨6.47%，近20日涨2.58%，近60日跌10.70%。 今年以来睿智医药已经2次登上龙虎榜，最近一次登上龙虎榜为7月29日，当日龙虎榜净买入1.65亿元； 买入总计2.56亿元 ，占总成交额比16.71%；卖出总计9095.17万元 ，占总成交额比5.93%。 资料显示，睿智医药科技股份有限公司位于广东省广州市越秀区东风中路268号交易广场28楼，成立日 期2000年1月26日，上市日期2010年12月22日，公司主营业务涉及医药研发与生产外包服务、微生态营 养、微生态医 ...

舒泰神所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：生物医药、抗癌治癌、创 新药、仿制药、AI医药等。 截至9月30日，舒泰神股东户数4.65万，较上期增加46.97%；人均流通股9745股，较上期减少31.98%。 2025年1月-9月，舒泰神实现营业收入1.81亿元，同比减少30.82%；归母净利润-3068.95万元，同比减少 227.71%。 分红方面，舒泰神A股上市后累计派现7.71亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，舒泰神十大流通股东中，兴全合润混合A（163406）位居第三大 流通股东，持股1226.91万股，相比上期减少345.19万股。兴全合宜混合A（163417）位居第五大流通股 东，持股933.96万股，相比上期增加338.75万股。易方达医疗保健行业混合A（110023）位居第八大流 通股东，持股583.89万股，持股数量较上期不变。兴全商业模式混合(LOF)A（163415）、兴全新视野 定期开放混合型发起式（001511）、永赢医药创新智选混合发起A（015915）退出十大流通股东之列。 11月14日，舒泰神盘中上涨2.04 ...

Core Viewpoint - Yipinhong's stock price has shown significant volatility, with a year-to-date increase of 207.74%, but recent trends indicate a decline over the past 60 days [1][2]. Company Overview - Yipinhong Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 4, 2002. It was listed on November 16, 2017. The company focuses on the research, production, and sales of its own pharmaceuticals, as well as the sales of agent pharmaceuticals [1]. - The main revenue composition includes children's medicine (61.12%), chronic disease medicine (22.71%), and others (16.17%) [1]. Financial Performance - For the period from January to September 2025, Yipinhong reported an operating income of 814 million yuan, a year-on-year decrease of 34.35%. The net profit attributable to the parent company was -136 million yuan, an increase of 44.80% year-on-year [2]. - Since its A-share listing, Yipinhong has distributed a total of 335 million yuan in dividends, with 151 million yuan distributed over the past three years [3]. Shareholder Information - As of October 31, 2025, Yipinhong had 20,700 shareholders, an increase of 9.42% from the previous period. The average circulating shares per person decreased by 8.61% to 20,156 shares [2]. - Notable new shareholders include Hong Kong Central Clearing Limited, holding 4.1496 million shares, and several mutual funds entering the top ten circulating shareholders [3]. Market Activity - On November 14, Yipinhong's stock rose by 2.02%, reaching 52.50 yuan per share, with a trading volume of 165 million yuan and a turnover rate of 0.77%. The total market capitalization is 23.714 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" five times this year, with the most recent appearance on July 21, where it recorded a net purchase of 65.576 million yuan [1].